New eye drops aim to boost tears in dry eye sufferers
NCT ID NCT06544707
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 3b trial tested AR-15512 eye drops in 81 adults with dry eye disease. The goal was to see if a single dose could quickly increase tear production, measured by tear meniscus height. The study was open-label, meaning everyone knew they were getting the active drug, and results will show how well it works in the short term.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AR-15512 ophthalmic solution (0.003%)
- What this could lead to
- If successful, this could provide a new eye drop option to quickly increase tear production and relieve dry eye symptoms.
- What could go wrong
- This is a small, completed Phase 3b study without a placebo group, so results may not prove long-term effectiveness or safety. Dry eye treatments often help some people but not others.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Eye Research Foundation
Newport Beach, California, 92663, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dry eye gel may sharpen cataract surgery results
- New eye drops could bring relief to millions with chronic dry eye
- Could stem cell eye drops soothe dry eyes?
- Second plug may boost dry eye comfort
- New AI reads eye scans to diagnose dry eye instantly
- Popular diabetes drugs may ease dry eye, study suggests